Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
He's the third reliever to leave the AL Central champions this winter, following Eli Morgan and Nick Sandlin, who were both traded.
Eli Lilly’s chief scientific officer said the company purchased a cancer drug from the startup Scorpion Therapeutics because ...
He’s the third reliever to leave the AL Central champions this winter, following Eli Morgan and Nick Sandlin, who were both traded.
Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan Healthcare Conference with a deal to buy Scorpion Therapeutics ...
Eli Lilly and Co., which cemented its place in ... life science firms presenting at J.P. Morgan As part of the deal, Scorpion is going to undergo a shakeup. The Boston biotech is going to spin ...
such as Eli Lilly's Zepbound or Novo Nordisk's Wegovy -- they've made headlines as demand for them soared. The obesity drug market may reach beyond $100 billion by 2030, according to Morgan ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback